Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Trial Profile

A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs E6 TCR (Primary) ; Aldesleukin
  • Indications Cervical intraepithelial neoplasia
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 5 Feb 2020 to 5 Feb 2021.
    • 09 Jan 2018 Planned initiation date changed from 26 Dec 2017 to 15 Jan 2018.
    • 14 Dec 2017 Planned initiation date changed from 30 Nov to 26 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top